Sale of our Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia
SEQENS today announced the sale of its Botanical Actives and In Vitro Diagnostics (“IVD”) activities located in Limoges (France) to Solabia, a global player specializing in high‑value natural ingredients for personal care, life sciences and diagnostics applications.
This transaction is fully aligned with SEQENS’ strategic roadmap, which focuses on strengthening its core Pharmaceutical Solutions and selective Specialty Ingredients activities. The divestment enables SEQENS to further concentrate its resources on its strategic priorities, while ensuring a solid and long‑term industrial future for the Limoges site within a group whose core mission is fully aligned with its activities.
Through its integration into Solabia, the Limoges facility will benefit from a shareholder with a strong scientific culture, recognized expertise in botanical actives and diagnostics, and a long‑term development vision dedicated to personal care and life science markets, allowing the site and its teams to fully realize their potential.
Pascal Villemagne, CEO of SEQENS, commented: “This transaction is fully consistent with our long‑term strategic vision. It enables Seqens to further focus on its core priorities, while ensuring that the Limoges teams join a group whose industrial culture, scientific expertise and growth ambitions are strongly aligned with their activities. We are confident that this new chapter with Solabia offers a robust and sustainable platform for the continued development of the site, its people and its know‑how.”
In parallel, SEQENS reaffirms its strong commitment to the Personal Care market. The Group will continue to support its customers through a focused portfolio built around its strategic segments, including nontraditional preservative solutions and performance ingredients, salicylic acid and derivatives, biotech-based ingredients, as well as custom solutions.
About SOLABIA:
Solabia is a vertically integrated manufacturer of natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, biotechnology and microbiology industries. Solabia is also a producer of culture media, supplements and detection kits for food testing, pharmaceutical industry and microbiology laboratories. With eleven production facilities and multiple R&D centers, Solabia is a major player in the global cosmetics, nutraceutical and pharmaceutical ingredient markets with presence in North and South America, Europe, Asia, Middle-East and Africa.
More information can be found at: https://www.solabia.com/en
About SEQENS:
SEQENS is a world leader in the development and production of active pharmaceutical ingredients, intermediates and specialty ingredients, with 15 production sites, 5 R&D centers and 2,700 employees on 3 continents.
As an integrated player across the entire value chain – from raw materials to active ingredients and from R&D to industrialization – SEQENS offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies.
